The Odisha market witnessed the highest growth
The Indian Pharma Market (IPM) has clocked Rs 8460 crores in June 2016 and has grown at 6.4 per cent. IPM has crossed Rs 1 lakh crores on MAT Basis.
Amongst the top 10 corporates, Mankind grew at 18.9 per cent, Macleods at 11.7 per cent followed by Alkem at 9.7per cent. 29 corporates have crossed the growth of IPM amongst top 50. Amongst the top 50 corporates, Bharat Serum has the highest growth of 40.2 per cent followed by Eris at 20.7 per cent and Medley at 19 per cent. 21 corporates have shown growths of more than 10 per cent amongst the top 50.
Amongst the 11-20 ranked corporates, Alembic had the highest growth of 11.3 per cent followed by Micro at 10.1 per cent and USV at 8.8 per cent. Amongst the 21-30 ranked corporates, Eris had the highest growth at 20.7 per cent followed by Indoco at 11.5 per cent and Unichem at seven per cent.
Amongst the 31-40 ranked corporates, Bharat Serums grew at 40.2 per cent followed by Franco at 16.2 per cent and JBCPL at 15.9 per cent. Amongst the 41-50 ranked corporates, Medley had the highest growth at 19 per cent followed by Apex Lab at 17.5 per cent and Systopic at 16.6 per cent. Amongst the 51-60 ranked corporates, Fresenius Kabi grew at 57.3 per cent followed by Boehringer Ingelheim at 50.1 per cent and Corona at 28.9 per cent.
Amongst the 61-70 ranked corporates, Shreya grew at 17.7 per cent followed by Geno at 15.5 per cent and RPG at 14.1 per cent. Amongst the 71-80 ranked corporates, Samarth grew by 15.9 per cent followed by Lincoln grew at 15.1 per cent and Bestochem at 12.4 per cent.
Amongst the 81 -90 ranked corporate, Galpha grew at 39.3 per cent followed by Veritaz grew at 34.8 per cent followed by Paras at 25.8 per cent. USV entered the Rs 2000-crore club on MAT Basis, whereas Ordain and Gland crossed Rs 100 crores on MAT Basis.
The 100th biggest corporate is Serum Institute and 150th biggest corporate is Shield in the IPM.
Abbott HC grew at 6.1 per cent whereas Abbott India grew at 3.9 per cent. Zuventus grew at 18.6 per cent. Indian companies have grown at 7.6 per cent versus two per cent for MNCs in June 2016. Amongst the top 50 in MNCs, Janssen grew at 13.2 per cent followed by Allergan at 11.1 per cent and Merck at 7.5 per cent. Under the Non-NLEM category, Indian companies grew at -0.6 per cent whereas MNCs grew at -4.0 per cent.
The NLEM 2013 containing molecules market grew at -1.5 per cent whereas the non-NLEM market grew by eight per cent resulting in an overall growth of 6.4 per cent for June 2016. The NLEM and Non-NLEM Category showed unit growth of three per cent and -1.5 per cent respectively.
10 therapies have outgrown the IPM growth. The respiratory market grew at 8.2 per cent, gastrointestinal market grew at 8.8 per cent , pain and analgesics market grew at 3.5 per cent whereas anti-infectives grew at 3.4 per cent. The anti-diabetics market grew at 11.7 per cent and cardiac at 3.9 per cent, Neuro/ CNS at 5.2 per cent in chronic business. The anti-malarials market grew at -2.4 per cent, VMS Market at 6.4 per cent, derma market by 8.5 per cent and urology market at 9.4 per cent.
From regional perspective, 15 regions have outgrown the IPM growth. The Odisha market grew the highest at 17.9 per cent followed by Haryana at 14.9 per cent and North East at 12.3 per cent. Two regions had negative growth in June 2016. Amoxycillin + Clavulanic Acid market grew at 3.2 per cent and Glimepiride + Metformin market grew at 17.2 per cent.
The markets of paracetamol grew at 14.3 per cent, atorvastatin -14.9 per cent, probiotic microbes at 26.8 per cent, bacillus clausii market at 38.5 per cent, cefixime at 4.1 per cent, pantoprazole at 10.2 per cent, montelukast + levocetrizine at 10.7 per cent, glimepiride + metformin + pioglitazone at -17.4 per cent, Vitamin-D at 12.6 per cent, Hydroquinone + Mometasone + Tretinoin at zero per cent, Voglibose + Metformin + Glimepiride at 39.4 per cent, rosuvastatin at 8.5 per cent, protein supplements at 6.5 per cent, azithromycin at 1.6 per cent, calcium carbonate + Vit D3 market at 4.4 per cent, paracetamol + phenylephrine + chlorpheniramine at 11 per cent, meropenem at 17.6 per cent, montelukast + fexofenadine at 14.2 per cent, diclofenac at 14.1 per cent, telmisartan at -10.7 per cent, levetiracetam at 12.9 per cent.
The 50th biggest market is piperacillin + tzobactam and 100th biggest market is ramipril for June 2016.
Mixtard led the pack with Rs 35 crores followed by Glycomet GP at Rs 32 crores, Lantus at Rs 27 crores and Liv-52 at Rs 25 crores.
Few brands who have gained ranks include Meronem (+56), Unwanted Kit (+45), Revital H (+35), Trajenta (+32), Duolin (+31), Udiliv, Mucaine (+28), Rantac (+23), Gluconorm G (+22), Levipil (+18), Levera (+17), Volini, Monocef O (+13), Januvia, Duphaston, Eltroxin (+12), Zifi, Budecort, Allegra (+11),Zinetac (+10), Janumet (+9), Foracort, Rosuvas, Istamet, Telma H, Sinarest (+8), Ultracet (+7), Voveran, Pan-D, Zoryl M (+6), Betadine, Pan, Calpol (+5), Lantus, Dolonex, Clexane (+4), Corex, Galvus Met, Clavam, Taxim O, Zincovit, Seroflo (+3), Gemer, Mikacin, Mox (+2) amongst top 100 brands over June 2015.
Hucog HP, Amlokind AT, Glimestar M, Lonopin, Advent, Glyciphage, P, Cilacar, Ecosprin AV,O2, Enterogermina are few brands which have gained ranks in 101-200 ranked brands. Few brands that have moved up ranks fastest into Top 300 brands are Imicrit, Trajenta Duo, Candiforce, Glimestar M, Corex DX, Grilinctus. The 300th biggest brand was Plavix from Sanofi.
A total of 324 brands and 526 SKUs were launched in June 2016. Top five new brands were Micedge, Tenglyn M, Rosuva Gold, Sudin Gold and Infusamin. The biggest launch by an MNC was Rebif by Merck. Two brands were launched each in Teneligliptin Market – Tenglyn M (Zydus) and Tenepan (Panacea).
Within the VMS category, Folican Plus (Med Manor), Gym (Delcure) & Osteo Plus M (Medsol India), in anti-diabetics Tenglyn M (Zydus), Gluformin I (Abbott) & Tenepan (Panacea), in derma Funzi NM (Corona), Mycoderm NM (FDC),Prickly Heat (Himalaya), in gynaec, 9FB (Indoco), Fibroeae (Akumentis), Pregcert AQ (Koye), in pain and analgesics category, Dilcotroy QPS (Troikaa), Lidogab, Walkrite (Delcure) and in the respiratory, Respicure M (Corona), L Montus ABL (Fourrts), Coekastle AX (Koye) were launched.
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocdawacs.com